How many Pozelimab clinical trials are there?

18 Pozelimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 6 are marked completed.

Are Pozelimab clinical trials recruiting in 2026?

Yes — 6 Pozelimab trials are actively recruiting in 2026, with 148 U.S. sites across 31 states. See the recruiting trials and the per-state site list further down this page.

What conditions is Pozelimab being studied for?

Pozelimab is being studied for Paroxysmal Nocturnal Hemoglobinuria, CD55-deficient Protein-losing Enteropathy, Geographic Atrophy (GA), Healthy, Generalized Myasthenia Gravis and 7 more. The trials are grouped by indication on this page.

What phase is Pozelimab in?

Pozelimab clinical trials span 1 Phase 4, 6 Phase 3, 2 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.

Who sponsors Pozelimab clinical trials?

The lead sponsor across the most Pozelimab trials is Regeneron Pharmaceuticals, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Pozelimab Clinical Trials (2026): 18 Studies for Paroxysmal Nocturnal Hemoglobinuria & CD55-deficient Protein-losing Enteropathy

Creator: Hipa.ai Research
Published: 2026-05-14T22:06:10.617Z

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: June 18, 2026.

18 Pozelimab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 10 indications (including Paroxysmal Nocturnal Hemoglobinuria & CD55-deficient Protein-losing Enteropathy) and 1,903 total planned enrollment. 6 Phase 3 Pozelimab trials and 2 Phase 2, 1 Phase 4 are listed. 6 Pozelimab clinical trials are actively recruiting at 148 U.S. sites across 31 states. Most recent activity: NCT06541704 (May 2032).

Where to Participate: All Pozelimab Trial Sites in the U.S. (148 sites across 31 states)

Every actively recruiting Pozelimabtrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

State	Facility	City	Trial	Map
AZ	Barnet Dulaney Perkins Eye Center-Ophthamalogy	Chandler85224	NCT06541704	Map
AZ	Associated Retina Consultants	Phoenix85020	NCT06541704	Map
AZ	Barnet Dulaney Perkins Eye Center	Phoenix85016	NCT06541704	Map
AZ	Retinal Research Institute	Phoenix85053	NCT06541704	Map
AZ	Retina Macula Institute of Arizona	Scottsdale85255	NCT06541704	Map
AZ	Retina Associates of Tuscan	Tucson85712	NCT06541704	Map
AR	Retina Partners of Northwest Arkansas, PLLC	Springdale72764	NCT06541704	Map
CA	Retina Specialists of Beverly Hills- Department of Ophthalmology	Beverly Hills90212	NCT06541704	Map
CA	Retina Vitreous Associates Medical Group	Beverly Hills90211	NCT06541704	Map
CA	Eye Medical Center of Fresno	Fresno93720	NCT06541704	Map
CA	Salehi Retina Institute dba Retina Associates of Southern California	Huntington Beach92647	NCT06541704	Map
CA	University of California Irvine	Irvine92617	NCT06541704	Map
CA	University of California San Diego, Jacobs Retina Center	La Jolla92093	NCT06541704	Map
CA	South Coast Retina Center	Long Beach90807	NCT06541704	Map
CA	Jules Stein Eye Institute in David Geffen School of Medicine at Ucla	Los Angeles90095	NCT06541704	Map
CA	Kaiser Permanente Los Angeles Medical Center	Los Angeles90027	NCT06541704	Map
CA	Retinal Consultants Medical Group Inc Modesto	Modesto95356	NCT06541704	Map
CA	Northern California Retina Vitreous Associates Medical Group, Inc.	Mountain View94040	NCT06541704	Map
CA	California Retina Consultants	Oxnard93036	NCT06541704	Map
CA	California Eye Specialists Medical Group Inc.	Pasadena91107	NCT06541704	Map
CA	Retina Consultants San Diego	Poway92064	NCT06541704	Map
CA	California Eye Specialists Medical Group, Inc.	Redlands92373	NCT06541704	Map
CA	Optic Eye Care	Rowland Heights91748	NCT06541704	Map
CA	Retinal Consultants Medical Group (RCMG) - Greenback Lane Retina Center	Sacramento95841	NCT06541704	Map
CA	UC Davis Health Eye Center	Sacramento95817	NCT06541704	Map
CA	Vrmg Inc	Sacramento95825	NCT06541704	Map
CA	West Coast Retina Medical Group, Inc.	San Francisco94109	NCT06541704	Map
CA	Orange County Retina Medical Group	Santa Ana92705	NCT06541704	Map
CA	Macula Retina Vitreous Research Institute	Torrance90503	NCT06541704	Map
CO	University of Colorado	Aurora80045	NCT06541704	Map
CO	Retina Consultants of Southern Colorado	Colorado Springs80909	NCT06541704	Map
CO	Retina Specialists of Colorado - Denver	Denver80222	NCT06541704	Map
CO	Southwest Retina Research Center	Durango81303	NCT06541704	Map
CO	Colorado Retina - Lakewood	Lakewood80228	NCT06541704	Map
CO	Colorado Retina Associates	Lakewood80228	NCT07230834	Map
CO	Eye care Center of Northern Colorado doing business as Advanced Vision Research Institute	Longmont80503	NCT06541704	Map
FL	Advanced Retina Institute-Ophthalmology	Bonita Springs34134	NCT06541704	Map
FL	Advanced Research	Coral Springs33067	NCT06541704	Map
FL	Retina Group of Florida	Fort Lauderdale33308	NCT06541704	Map
FL	ClearVista Clinical Research, Retina Center Tampa Bay	Hudson34667	NCT06541704	Map
FL	Florida Retina Institute, Jacksonville Perimeter Park- Ophthalmology	Jacksonville32216	NCT06541704	Map
FL	Florida Retina Consultants	Lakeland33805	NCT06541704	Map
FL	Bascom Palmer Eye Institute	Naples34103	NCT06541704	Map
FL	Florida Retina Institute - Orlando	Orlando32806	NCT06541704	Map
FL	Retina Care Specialists	Palm Beach Gardens33410	NCT06541704	Map
FL	Eye Associates of Pinellas	Pinellas Park33782	NCT06541704	Map
FL	Retina Group of Florida, RAS-Sarasota Retina Center-Ophthalmology	Sarasota34232	NCT06541704	Map
FL	Retina Vitreous Associates of Florida Saint Petersburg	St. Petersburg33711	NCT06541704	Map
FL	University of South Florida Ophthalmology	Tampa33612	NCT06541704	Map
FL	Center for Retina and Macular Disease	Winter Haven33880	NCT06541704	Map
GA	Southeast Retina Center	Augusta30909	NCT06541704	Map
GA	Georgia Retina - Marietta	Marietta30060	NCT06541704	Map
IL	Retinal Vitreal Consultants	Chicago60616	NCT06541704	Map
IL	The University of Chicago	Chicago60637	NCT06541704	Map
IL	University of Illinois at Chicago	Chicago60612	NCT06541704	Map
IL	University Retina and Macula Associates PC - Lemont	Lemont60439	NCT06541704	Map
IL	Illinois Retina Associates	Oak Park60304	NCT06541704	Map
IL	Springfield Clinic Main Campus East	Springfield62703	NCT06541704	Map
KS	Retina Associates, LLC	Lenexa66215	NCT06541704	Map
KY	University of Louisville	Louisville40202	NCT06541704	Map
LA	Retina Associate New Orleans	Metairie70001	NCT06541704	Map
LA	Ross Davis Retina	Metairie70006	NCT06541704	Map
LA	Ochsner Health	New Orleans70121	NCT06541704	Map
LA	Eye Assoc. of NE LA dba Haik Humble Eye Ctr	West Monroe71291	NCT06541704	Map
LA	Eye Associates of Northeast Louisiana dba Haik Humble Eye Center	West Monroe71291	NCT06541704	Map
MD	The Retina Care Center	Baltimore21209	NCT06541704	Map
MD	The Retina Group of Washington	Chevy Chase20815	NCT06541704	Map
MD	Cumberland Valley Retina Consultants-Ophthalmology	Hagerstown21740	NCT06541704	Map
MD	Mid Atlantic Retina Specialist	Hagerstown21740	NCT06541704	Map
MA	Massachusetts Eye And Ear Infirmary	Boston02114	NCT06541704	Map
MA	Opthalmic Consultants of Boston	Boston02114	NCT06541704	Map
MA	Ophthalmic Consultants of Boston	East Weymouth02189	NCT07230834	Map
MA	New England Retina Consultants, PC	Springfield01107	NCT06541704	Map
MA	Vitreo-Retinal Associates PC	Worcester01605	NCT06541704	Map
MI	Retina Associates of Michigan	Grand Blanc48439	NCT06541704	Map
MS	Mississippi Retina Associates	Madison39110	NCT06541704	Map
MS	Deep Blue Retina Clinical Research PLLC	Southaven38671	NCT06541704	Map
MO	Retina Research Institute, LLC	St Louis63144	NCT06541704	Map
NJ	Mid Atlantic Retina - Cherry Hill	Cherry Hill08034	NCT06541704	Map
NJ	New Jersey Retina	Teaneck07666	NCT06541704	Map
NJ	New Jersey Retina	Toms River08755	NCT06541704	Map
NM	Vision Research Center at Eye Associates of New Mexico	Albuquerque87109	NCT06541704	Map
NY	Sight MD	Brentwood11717	NCT06541704	Map
NY	Retina Vitreous Surgeons of Central New York, PC	Liverpool13088	NCT06541704	Map
NY	New York Ear & Eye- East 85th	New York10028	NCT06541704	Map
NY	Northwell Health- Manhattan, Ear, Eye and Throat Hospital- Ophthalmology	New York10065	NCT06541704	Map
NY	Retina Associates of New York, Upper East Side	New York10075	NCT06541704	Map
NY	Seeta Eye center	Poughkeepsie12603	NCT06541704	Map
NC	Western Carolina Retinal Associates	Asheville28803	NCT06541704	Map
NC	NC Retina Associates	Cary27511	NCT06541704	Map
NC	Graystone Eye	Hickory28602	NCT06541704	Map
NC	North Carolina Retina Associates	Wake Forest27587	NCT06541704	Map
NC	Piedmont Retina Specialist	Winston-Salem27103	NCT06541704	Map
OH	Cincinnati Eye Institute	Cincinnati45242	NCT06541704	Map
OH	University Hospitals Cleveland Medical Center	Cleveland44106	NCT06541704	Map
OH	The Ohio State University	Columbus43212	NCT06541704	Map
OH	Midwest Retina, Inc	Dublin43016	NCT06541704	Map
OK	Retina Vitreous Center - Edmond	Edmond73013	NCT06541704	Map
OK	Tulsa Retina Consultants	Tulsa74114	NCT06541704	Map
OR	Verum Research LLC	Eugene97401	NCT06541704	Map
OR	EyeHealth Northwest	Portland97225	NCT06541704	Map
OR	OHSU-Casey Eye Institute, Marquam Hill-Ophthalmology	Portland97239	NCT06541704	Map
OR	Retina Northwest, The Highlands Building	Portland97221	NCT06541704	Map
OR	Cascade Medical Research Institute LLC	Springfield97477	NCT06541704	Map
PA	Mid Atlantic Retina	Bethlehem18017	NCT06541704	Map
PA	Erie Retinal Surgery & Erie Retina Research	Erie16507	NCT06541704	Map
PA	Mid Atlantic Retina, Wills Eye Hospital	Philadelphia19107	NCT06541704	Map
PA	Vision Research Solutions - the Eye Institute	Philadelphia19141	NCT06541704	Map
PA	Sewickley Eye Group	Sewickley15143	NCT06541704	Map
SC	Retina Consultants of Carolina	Greenville29605	NCT06541704	Map
SC	Charleston Neuroscience Institute LLC	Ladson29456	NCT06541704	Map
SC	Charleston Neuroscience Institute, LLC	Mt. Pleasant29464	NCT06541704	Map
SC	Palmetto Retina Center	West Columbia29169	NCT06541704	Map
SD	Black Hills Regional Eye Institute	Rapid City57701	NCT06541704	Map
TN	Tennessee Retina, PC	Nashville37203	NCT06541704	Map
TN	Vanderbilt Eye Institute	Nashville37232	NCT06541704	Map
TX	Retina Research Institute of Texas	Abilene79606	NCT06541704	Map
TX	Austin Neuromuscular Center	Austin78759	NCT06479863	Map
TX	Austin Neuromuscular Center	Austin78759	NCT06479863	Map
TX	Austin Research Center for Retina	Austin78705	NCT06541704	Map
TX	Austin Retina Associates	Austin78705	NCT06541704	Map
TX	Austin Retina Associates	Austin78705	NCT07230834	Map
TX	Retina Consultants Texas	Bellaire77401	NCT06541704	Map
TX	Star Retina PLLC	Burleson76028	NCT06541704	Map
TX	Retina Foundation of the Southwest	Dallas75231	NCT06541704	Map
TX	Retina Foundation of the Southwest	Dallas75231	NCT07230834	Map
TX	Texas Retina Associates	Dallas75231	NCT06541704	Map
TX	University of Texas Southwestern Medical Center	Dallas75390	NCT06541704	Map
TX	Retina Consultants of Texas	Katy77494	NCT06541704	Map
TX	Valley Retina Institute, P.A.	McAllen78503	NCT06541704	Map
TX	Austin Retina Associates	Round Rock78681	NCT06541704	Map
TX	Medical Center Ophthalmology Associates	San Antonio78240	NCT06541704	Map
TX	Retina Associates of South Texas	San Antonio78240	NCT06541704	Map
TX	Retina Consultants of Texas	San Antonio78240	NCT06541704	Map
TX	Retina Consultants of Texas Brown Retina Institute	San Antonio78251	NCT06541704	Map
TX	Retina Center of Texas	Southlake76092	NCT06541704	Map
TX	Retina Consultants Texas	The Woodlands77384	NCT06541704	Map
TX	Retina Consultants Texas	The Woodlands77384	NCT07230834	Map
TX	Tyler Retina Research Institute- Ophthalmology	Tyler75703	NCT06541704	Map
UT	Retina Associates Of Utah Retina Specialist	Salt Lake City84107	NCT06541704	Map
UT	Rocky Mountain Retina Consultants	Salt Lake City84107	NCT06541704	Map
UT	Salt Lake Retina- Ophthalmology	West Jordan84088	NCT06541704	Map
VT	University of Vermont	Burlington05401	NCT06541704	Map
VA	Southeastern Retina Associates	Bristol24201	NCT06541704	Map
VA	Retina Group of Washington	Fairfax22031	NCT06541704	Map
VA	Piedmont Eye Center	Lynchburg24502	NCT06541704	Map
VA	Virginia Eye Institute	Richmond23226	NCT06541704	Map
WA	Spokane Eye Clinical Research	Spokane99204	NCT06541704	Map

Pozelimab clinical trials at a glance: phase × recruitment status

Phase	recruiting	active not recruiting	completed	terminated	no longer available	approved for marketing	Total
Early P1	1						1
P1	1		3				4
P2			2				2
P2/P3			1				1
P3	3	2		1			6
P4	1						1
N/A					1	2	3

Recruiting Pozelimab clinical trials (6)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT ID	Title	Phase	Indication	Enrollment	Started
NCT06541704	SIENNAA Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy	P3	Age-related Macular Degeneration (AMD)	975	Oct 2024
NCT07154745	PNHA Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently	P3	Paroxysmal Nocturnal Hemoglobinuria	35	May 2026
NCT07142343	A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease	P4	CHAPLE Disease	5	Mar 2026
NCT05744921	ACCESS-EXTA Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works	P3	Paroxysmal Nocturnal Hemoglobinuria	202	Mar 2023
NCT07230834	VIENNAIntravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants	P1	Geographic Atrophy (GA)	54	Jan 2026
NCT06479863	Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis	Early P1	Sporadic Inclusion Body Myositis (sIBM)	10	Aug 2024

Pozelimab clinical trials by indication

Paroxysmal Nocturnal Hemoglobinuria (7)

NCT	Acronym	Phase	Status	Title
NCT07154745	PNH	P3	recruiting	A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently
NCT05744921	ACCESS-EXT	P3	recruiting	A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
NCT05133531	ACCESS-1	P3	active not recruiting	A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment
NCT04811716	—	P2	completed	Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy
NCT06028594	—	N/A	no longer available	Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT05131204	ACCESS 2	P3	terminated	Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04888507	—	P2	completed	Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Healthy (2)

NCT	Acronym	Phase	Status	Title
NCT04940364	—	P1	completed	A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers
NCT04601844	—	P1	completed	Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers

CD55-deficient Protein-losing Enteropathy (2)

NCT	Acronym	Phase	Status	Title
NCT04209634	—	P2/P3	completed	Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)
NCT05232110	—	N/A	approved for marketing	Compassionate Use of Pozelimab

CHAPLE Disease (1)

NCT	Acronym	Phase	Status	Title
NCT07142343	—	P4	recruiting	A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease

Geographic Atrophy (GA) (1)

NCT	Acronym	Phase	Status	Title
NCT07230834	VIENNA	P1	recruiting	Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Age-related Macular Degeneration (AMD) (1)

NCT	Acronym	Phase	Status	Title
NCT06541704	SIENNA	P3	recruiting	A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Sporadic Inclusion Body Myositis (sIBM) (1)

NCT	Acronym	Phase	Status	Title
NCT06479863	—	Early P1	recruiting	Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis

Generalized Myasthenia Gravis (1)

NCT	Acronym	Phase	Status	Title
NCT05070858	NIMBLE	P3	active not recruiting	A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis

Healthy Volunteer (1)

NCT	Acronym	Phase	Status	Title
NCT04491838	—	P1	completed	Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants

CD55-Deficient Protein-Losing Enteropathy (1)

NCT	Acronym	Phase	Status	Title
NCT06003881	CHAPLE Disease	N/A	approved for marketing	Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy

Pozelimab pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

Acronym	NCT	Phase	Status	Indication	Enrollment	PubMed
SIENNA	NCT06541704	P3	recruiting	Age-related Macular Degeneration (AMD)	975	—
PNH	NCT07154745	P3	recruiting	Paroxysmal Nocturnal Hemoglobinuria	35	—
ACCESS-EXT	NCT05744921	P3	recruiting	Paroxysmal Nocturnal Hemoglobinuria	202	—
NIMBLE	NCT05070858	P3	active not recruiting	Generalized Myasthenia Gravis	288	PMID 42030965
ACCESS-1	NCT05133531	P3	active not recruiting	Paroxysmal Nocturnal Hemoglobinuria	202	—
ACCESS 2	NCT05131204	P3	terminated	Paroxysmal Nocturnal Hemoglobinuria	3	—

Terminated and withdrawn Pozelimab trials (1)

Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.

NCT05131204terminatedEfficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria

All Pozelimab trials (18)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT ID	Acronym	Title	Phase	Status	Enrollment	Sponsor	Started
NCT06541704	SIENNA	A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy	P3	recruiting	975	Regeneron Pharmaceuticals	Oct 2024
NCT07154745	PNH	A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently	P3	recruiting	35	Regeneron Pharmaceuticals	May 2026
NCT07142343		A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease	P4	recruiting	5	Regeneron Pharmaceuticals	Mar 2026
NCT05744921	ACCESS-EXT	A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works	P3	recruiting	202	Regeneron Pharmaceuticals	Mar 2023
NCT05070858	NIMBLE	A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis	P3	active not recruiting	288	Regeneron Pharmaceuticals	Dec 2021
NCT07230834	VIENNA	Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants	P1	recruiting	54	Regeneron Pharmaceuticals	Jan 2026
NCT06479863		Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis	Early P1	recruiting	10	Austin Neuromuscular Center	Aug 2024
NCT05133531	ACCESS-1	A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment	P3	active not recruiting	202	Regeneron Pharmaceuticals	Aug 2022
NCT04209634		Open-Label Efficacy and Safety Study of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy (CHAPLE Disease)	P2/P3	completed	10	Regeneron Pharmaceuticals	Jan 2020
NCT04811716		Pozelimab and Cemdisiran Combination Treatment in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy	P2	completed	24	Regeneron Pharmaceuticals	Jul 2021
NCT06028594		Compassionate Use of Pozelimab and Cemdisiran Combination Therapy in Patients With Paroxysmal Nocturnal Hemoglobinuria	—	no longer available	0	Regeneron Pharmaceuticals	—
NCT06003881	CHAPLE Disease	Compassionate Use of Pozelimab in Patients With CD55-Deficient Protein-Losing Enteropathy	—	approved for marketing	0	Regeneron Pharmaceuticals	—
NCT05131204	ACCESS 2	Efficacy and Safety of the Combination of Pozelimab and Cemdisiran Versus Continued Eculizumab or Ravulizumab Treatment in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria	P3	terminated	3	Regeneron Pharmaceuticals	Oct 2022
NCT04888507		Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy	P2	completed	6	Regeneron Pharmaceuticals	Jul 2021
NCT04940364		A Study to Examine the Safety, Tolerability and Biological Effects of Single Doses of Subcutaneously and Intravenously Administered Pozelimab as Monotherapy and in Combination With Single Doses of Subcutaneously Administered Cemdisiran in Adult Japanese Healthy Volunteers	P1	completed	30	Regeneron Pharmaceuticals	Aug 2021
NCT05232110		Compassionate Use of Pozelimab	—	approved for marketing	0	Regeneron Pharmaceuticals	—
NCT04601844		Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Pozelimab in Combination With Cemdisiran in Healthy Adult Volunteers	P1	completed	19	Regeneron Pharmaceuticals	Nov 2020
NCT04491838		Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants	P1	completed	40	Regeneron Pharmaceuticals	Aug 2020

Pozelimab clinical trials: frequently asked questions

How many Pozelimab clinical trials are there?: 18 Pozelimab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 6 are actively recruiting participants. 6 are marked completed.
Are Pozelimab clinical trials recruiting in 2026?: Yes — 6 Pozelimab trials are actively recruiting in 2026, with 148 U.S. sites across 31 states. See the recruiting trials and the per-state site list further down this page.
What conditions is Pozelimab being studied for?: Pozelimab is being studied for Paroxysmal Nocturnal Hemoglobinuria, CD55-deficient Protein-losing Enteropathy, Geographic Atrophy (GA), Healthy, Generalized Myasthenia Gravis and 7 more. The trials are grouped by indication on this page.
What phase is Pozelimab in?: Pozelimab clinical trials span 1 Phase 4, 6 Phase 3, 2 Phase 2, 4 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors Pozelimab clinical trials?: The lead sponsor across the most Pozelimab trials is Regeneron Pharmaceuticals, with 1 additional lead sponsor listed in the data. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Pozelimabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed June 18, 2026.

Related pages on Hipa.ai:

Pozelimab overview Pozelimab evidence & publications